Hyperpolarized xenon MRI may be useful in assessing response to biologic treatment among patients with asthma, according to a ...

The investigational drug demonstrated robust STAT6 degradation in blood and skin that was well tolerated and safe in healthy ...

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...

Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...

The committee concluded that dupilumab does not represent a cost-effective use of resources, so could not be recommended for treating severe asthma with type 2 inflammation.

For COPD patients, the adage holds true: "the first way to get out of a hole is to quit digging one," said Christopher Mosher ...

KYMR jumps after KT-621 phase I data beats expectations, matching or topping Dupixent on key biomarkers in Th2 diseases.

Kymera Therapeutics is actively recruiting for its BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD), with results expected in the fourth quarter of 2025. Additionally, two parallel ...

Kymera Therapeutics (NASDAQ:KYMR) rose ~16% in after-hours trading Friday after the company announced it would release phase 1 data of its inflammatory diseases oral candidate KT-621 in healthy ...

Kymera Therapeutics Inc. (NASDAQ:KYMR) saw its stock jump 37.3% in premarket trading after the company announced strong Phase 1 trial results for KT-621, its oral STAT6 degrader targeting allergic and ...

Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials ...